EVOTEC SE ADR

NASDAQ: EVO (Evotec SE)

Last update: 25 Mar, 6:29AM

3.63

0.12 (3.42%)

Previous Close 3.51
Open 3.53
Volume 67,524
Avg. Volume (3M) 81,166
Market Cap 1,289,038,464
Price / Earnings (Forward) 59.88
Price / Sales 1.32
Price / Book 1.06
52 Weeks Range
2.85 (-21%) — 7.98 (119%)
Earnings Date 17 Apr 2025
Profit Margin -22.05%
Operating Margin (TTM) -17.68%
Diluted EPS (TTM) -0.550
Quarterly Revenue Growth (YOY) -5.80%
Total Debt/Equity (MRQ) 48.54%
Current Ratio (MRQ) 2.09
Operating Cash Flow (TTM) -36.05 M
Levered Free Cash Flow (TTM) -188.42 M
Return on Assets (TTM) -1.77%
Return on Equity (TTM) -16.25%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bearish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bearish Mixed
Stock Evotec SE Mixed Bearish

AIStockmoo Score

-2.0
Analyst Consensus -2.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 0.0
Technical Oscillators -4.0
Average -2.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
EVO 1 B - - 1.06
ALKS 4 B - 12.27 3.11
SUPN 2 B - 23.30 1.70
DVAX 1 B - 51.55 2.14
AMPH 1 B - 8.70 1.51
PETQ 917 M - 82.89 3.56

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Core
% Held by Institutions 2.52%

Ownership

Name Date Shares Held
Lighthouse Investment Partners, Llc 31 Dec 2024 39,803

No data within this time range.

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria